{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:04:39Z","timestamp":1786118679592,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,31]]},"DOI":"10.1097\/qad.0b013e328216f2c7","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T05:00:32Z","timestamp":1184302832000},"page":"1555-1559","source":"Crossref","is-referenced-by-count":31,"title":["Baseline factors prognostic of sustained virological response in patients with HIV\u2013hepatitis C virus co-infection"],"prefix":"10.1097","volume":"21","author":[{"given":"Gregory J","family":"Dore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca J","family":"Torriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Rodriguez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norber","family":"Br\u00e4u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard Sola","family":"Lamoglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Clumeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Mendes-Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot W","family":"Godofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas T","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Yetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2005.03.003","article-title":"Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients","volume":"42","author":"Alberti","year":"2005","journal-title":"J Hepatol"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1111\/j.1572-0241.2005.00222.x","article-title":"Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office","volume":"100","author":"Tien","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV\u2013HCV co-infection","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-140-5-200403020-00033","article-title":"Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?","volume":"140","author":"Zeuzem","year":"2004","journal-title":"Ann Intern Med"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0168-8278(02)00211-8","article-title":"Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40 kD)","volume":"37","author":"Lee","year":"2002","journal-title":"J Hepatol"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/00002030-199510000-00003","article-title":"High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV","volume":"9","author":"Cribier","year":"1995","journal-title":"AIDS"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep.510310131","article-title":"Is an \u201ca la carte\u201d combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group","volume":"31","author":"Poynard","year":"2000","journal-title":"Hepatology"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002030-200401020-00009","article-title":"Pegylated interferon alpha 2b and ribavirin in HIV\/hepatitis C virus co-infected nonresponders and relapsers to IFN-based therapy","volume":"18","author":"Myers","year":"2004","journal-title":"AIDS"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200707310-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:41:37Z","timestamp":1786034497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200707310-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328216f2c7","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,31]]}}}